Clostridium Difficile Diagnostics Market
The cause of many gastrointestinal conditions, including those characterised by diarrhoea, nauseousness, colon inflammation, and other symptoms, is Clostridium difficile. Stomach distension, excruciating abdominal pain, and profuse diarrhoea are life-threatening signs of the illness. The treatment of Clostridium difficile infections involves both the diagnosis of the infection using a variety of tests and the administration of medicines like Fidaxomicin and Vancomycin.
The market for clostridium difficile diagnostics is anticipated to reach US$ 838.05 million in 2022 and grow at a CAGR of 7.1% during the following five years (2022-2030).
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/5315
Market Drivers
The global market for clostridium difficile diagnostics is estimated to expand as a result of the rising prevalence of clostridium difficile infection (CDI), which is predicted to increase the demand for its diagnosis. For instance, data from Cureus, an open access medical journal, released in December 2021 shows that C. difficile infection (CDI) affects 13 out of every 1,000 patients globally, with approximately 75% of cases being categorised as hospital acquired. Increased incidence of healthcare-related CDI have been linked to higher rates of hospital admissions and antibiotic use (HA-CDI). Increased morbidity is associated with nosocomial CDI.
Additionally, over the course of the forecast period, regulatory agencies are anticipated to approve more diagnostic tests and assays. For instance, immunodiagnostics business Singulex, Inc. announced the commercial launch of their Clarity C. difftoxin A/B assay, a quick, sensitive, and accurate test for C. difficile toxin, in November 2018. The test has the same sensitivity and specificity as cell cytotoxicity neutralisation assays, which may lessen false positive results from polymerase chain reaction-based testing and false negative results from existing, less sensitive toxin immunoassays.
Impact
Three key ways in which COVID-19 has impacted the economy are: directly by altering the demand for and manufacturing of pharmaceuticals and vaccines; by causing disruptions in the channels of distribution; and by having an economic impact on businesses and financial markets. The global market for clostridium difficile diagnostics was not significantly impacted by COVID-19. For instance, according to a piece by Elsevier Inc., during the COVID-19 pandemic in August 2022, a number of variables, including increased hand cleanliness, social isolation, and limited hospital referral, may have had an impact on the epidemiology of Clostridioides difficile infections (CDI).
Key Developments
The two German businesses, Virotech Diagnostics GmbH and Novatec Immundiagnostica GmbH, joined together in 2021 to establish Gold Standard Diagnostics Europe. The newly established company is producing diagnostic kits for infectious diseases (bacterial, viral, and parasite disorders), hormones, and autoimmune, with a focus on both the human and animal industries.
Market: Restraint
The growth of the clostridium difficile diagnostics market is anticipated to be constrained over the projected period by low awareness of the symptoms and effects of clostridium difficile infection.
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/5315
Key Players
AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Novartis AG, Thermo Fisher Scientific, Sanofi S.A., Merck & Co., Inc., Summit Therapeutics, Pfizer, Inc., Trinity Biotech Plc., Actelion Pharmaceuticals, Inc., and Abbott Laboratories are significant market participants in the global clostridium difficile diagnostics market.
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Clostridium Difficile Diagnostics Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Clostridium Difficile Diagnostics Industry Impact
Chapter 2 Global Clostridium Difficile Diagnostics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Clostridium Difficile Diagnostics (Volume and Value) by Type
2.3 Global Clostridium Difficile Diagnostics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Clostridium Difficile Diagnostics Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Clostridium Difficile Diagnostics Market Analysis
Chapter 6 East Asia Clostridium Difficile Diagnostics Market Analysis
Chapter 7 Europe Clostridium Difficile Diagnostics Market Analysis
Chapter 8 South Asia Clostridium Difficile Diagnostics Market Analysis
Chapter 9 Southeast Asia Clostridium Difficile Diagnostics Market Analysis
Chapter 10 Middle East Clostridium Difficile Diagnostics Market Analysis
Chapter 11 Africa Clostridium Difficile Diagnostics Market Analysis
Chapter 12 Oceania Clostridium Difficile Diagnostics Market Analysis
Chapter 13 South America Clostridium Difficile Diagnostics Market Analysis
Chapter 14 Company Profiles and Key Figures in Clostridium Difficile Diagnostics Business
Chapter 15 Global Clostridium Difficile Diagnostics Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5315
About US
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com